Paysign
This is the archived full research. Read the story
A small payments company that pays plasma donors on prepaid cards and runs copay-assistance programs for drug makers.
The scores
Growth3/4 ↑
Pharma nearly doubles on 51 net new programs, but plasma grew 4.0% in 2025 and its center count is shrinking.
Business quality3/4 →
Near half of US plasma centers won from incumbents, but centers leave on a sale or a customer's bank tie, and McKesson dwarfs it.
Financial position4/4 ↑
Net cash, no debt, own cash flow covers investment; the only commitment is $6M to Gamma's sellers.
Execution record3/4 →
Beat and raised twice in 2026, but the software deal missed so badly its earn-out was zeroed, and FDA timing slipped.
Per share capture3/4 ↓
Diluted shares up 7.1% in a year with no buyback, and more units promised to Gamma's owner; growth still outruns it.
Potential2/4 →
Plasma is near half the centers already; pharma upside needs program wins nobody has signed and no federal maximizer rule.
Risk profile3/4 →
One drug maker is 36% of receivables and a federal maximizer rule would cut the product's edge; neither resolves in one step.
Valuation1/4 ↓
About 38.7 times earnings, 189% of a three-stage value near $6.62 at 8%: priced for perfection, beyond the 20% margin.
Evidence quality3/4 →
Filed figures and outside counts, but the product's value, the savings and the FDA timetable rest on management's word.
If it works 0.8× · if it fails you keep about 44%.
The Verdict
We rate Paysign Unattractive. It pays plasma donors on prepaid cards and runs the programmes drug makers use to cover patients' share of expensive medicines, and the copay side more than doubled in the latest quarter with real profit, so the business is strong. But a rule against copay-draining plans could remove its main appeal, one drug maker looms large, a plasma customer is moving 113 centres away and a software purchase failed. The price is nearly twice our value, above our best case. As a bet it is fragile: a little under half left if copay programmes stall.
The long caseInsurers keep finding ways to divert drug makers' copay aid, so drug makers pay administrators like Paysign to protect it, and each new program adds recurring fees.
How we weighed it
The price against our value
Against it
Price at 189% of our value
The price sits above our value and above the bull case.
The business
In its favour
Solid
A solid business whose copay side more than doubled with real profit.
Growth against what the price assumes
Cuts both ways
The price needs drug makers to keep adding programmes at a fast pace.
What could go wrong
Against it
A rule may remove its main appeal, one client is a large share and plasma centres are leaving.
Against competitors
Cuts both ways
No filed rival compares directly; against its own normal it is far dearer.
How its group is behaving
Cuts both ways
Fintech names move together on credit and rate news.
The latest news and report
In its favour
The last report delivered every number the thesis asked for.
The evidence under this - 8 claims
- 2026-11-09editedQ3 2026 release: 562 centers, and the notice that 113 centers leave by year-end
- Guidance has been raised twice this year; if 2026 lands at the Q2 run-rate plus seasonality the multiple is lower than 35.2.
- Trailing earnings include a 45.4% tax rate in Q4 2025 that depresses the trailing figure.
- 2026-11-09editedre-struck on the raised guide and the Q3 diluted share count, at the 6 November close
- 2026-11-10editedRe-struck at the 9 November close of $12.51 after the 10-Q: the shares fell 15% from the close the multiples were struck at
- 2026-11-09editedQ3 2026 release: 167 programs, 62 net added in twelve months; year-end guide 190 to 195
The equal split was stated in March, before the raise; if the raise was mostly pharma, pharma is larger than half.
- 2026-11-09editedthe March split put pharma at $56.5M; nine months already reached $46.95M, so the estimate was re-derived from the Q3 release
The company
Plasma collectors pay donors a fee after each visit. Paysign loads that fee onto a prepaid card, and CSL Plasma, one of the largest collectors, sends its donors to Paysign's app.
Drug makers help insured patients with the part of a drug's price their insurance leaves them to pay. Paysign runs those programs: it checks each claim at the pharmacy, pays the patient's share from the maker's fund and bills the maker back. The alternative is a rival administrator such as McKesson.
The evidence under this - 5 claims
Winning programs moved from incumbents proves programs can move, which means Paysign's can too; no count of programs lost is disclosed.
How it makes money
From plasma, it earns a fee each time a donor spends from the card: about $7,699 a month per center in Q2 2026. From drug makers, it earns set-up, monthly and per-claim fees, not a share of the money it pays out. More programs and more claims bring more fees. Nothing is paid on a percentage of the aid itself.
The evidence under this - 4 claims
- 2026-11-09editedQ3 2026 release: 167 programs, 62 net added in twelve months; year-end guide 190 to 195
Where the money comes from, stream by stream
| Stream | Share of sales (Q2 2026) | How it earns it |
|---|---|---|
| Pharma (patient affordability) | 51.9% | Fees per program and per claim from drug makers for running copay assistance cards and catching insurers' maximizer claims. |
| Plasma | 46.2% | Card program, cardholder and interchange fees on prepaid cards plasma centers use to pay donors. |
| Other | 2.0% | Corporate incentive, payroll, disbursement and gift card programs, earning card fees, interchange, breakage and settlement income. |
Who runs it
Mark Newcomer co-founded the business and has run it since 2006; he owns about a sixth of the company, and officers and directors together about a quarter, so management gains or loses with shareholders. Pay is loosely tied to results: bonuses are set by the board at its discretion, and most share awards vest simply by staying, with some tied to profit targets the company does not publish.
The evidence under this - 3 claims
- The earnings targets are not disclosed, so how hard they were to reach cannot be judged, and they were met in the first year of a three-year grant.
- The proxy says the company has not looked to net income or shareholder return to measure executive performance.
Why it wins, and who could beat it
Why customers come back
Switching is a nuisance. A collector that leaves must give every donor a new card, and a drug maker that moves a program risks patients' claims failing at the counter. Paysign holds 47.7% of US plasma centers by an outside count.
Its pitch to drug makers is catching insurers' plans that drain copay funds; those plans took $2.7B in 2023. Paysign says its rules saved clients $325M in 2025, but only Paysign measured that. And when collectors sell centers, the cards leave with them.
The evidence under this - 5 claims
Management says closures cost little because donors move to nearby Paysign centers, and revenue per center rose 8.5% while centers fell.
- No client or third party has published the savings; the $325M is the seller's own count of money it says it kept from insurers.
- The 97% first-fill detection rate management cites is also unaudited.
The threat
McKesson runs the same copay service at a far larger scale, saving patients about $10B a year against Paysign's $1B. Onbe, a private company, sells the same donor cards. For plasma software, Haemonetics already sells a cleared system linked to its own collection machines; Paysign's has no clearance.
The evidence under this - 4 claims
- The timetable has already slipped at least twice, from Q4 2025 to 'first quarter, second quarter' of 2026, and the Q1 2026 call would say nothing beyond 'discussions back and forth'.
- The FDA's 510(k) database shows no clearance for Paysign, Gamma or Apherion as of 2026-09-27.
The rivals: MCK, HAE, and 1 more that is private, in-house or listed abroad.
Who else does this, rival by rival
| Ticker | Rival | Where it competes | How far along | Priced against it |
|---|---|---|---|---|
| MCK | McKesson Prescription Technology SolutionsPriced against it: One segment only | Pharma industry | On sale | One segment only |
| Private | OnbePriced against it: Private | Plasma industry | On sale | Private |
| HAE | Haemonetics NexLynk DMSPriced against it: One segment only | Apherion software | On sale | One segment only |
How big it could get
How big this could get
If all 1,247 US plasma centers paid Paysign's current rate, plasma cards would bring in about $115.2M a year, against $45.62M in 2025. Paysign already has nearly half of them, so that business can grow mainly by taking more per center.
Drug makers spent $23B on copay aid in 2023; Paysign handled nearly $1B in 2025. Nobody publishes what administrators earn on that pool, so its size in fees is unknown.
The evidence under this - 4 claims
- No client or third party has published the savings; the $325M is the seller's own count of money it says it kept from insurers.
- The 97% first-fill detection rate management cites is also unaudited.
Where the growth is coming from, business by business
Where the growth is coming from
| Business | Share of revenue | Growth: last quarter | Last half-year | Last year | Share in 3 years at its half-year rate |
|---|---|---|---|---|---|
| Pharma industry | 54% | +109.8% | +99.5% | +99.0% | 87% |
| Plasma industry | 45% | +7.5% | +13.8% | +15.8% | 13% |
| Rest of the company | 1% | -56.7% | -34.4% | -6.6% | 0% |
| Whole company | 100% | +42.6% | +45.2% | +45.8% | 100% |
On the filed split through 2026-09-30, if each business keeps its last half-year's growth, the company grows about 60% next year and 81% in year 3, against 46.8% over the last twelve months. Pharma industry carries the case: it grows 99% against 13% for the rest, and would be 87% of revenue by then. A scenario, not a forecast: no business holds its rate.
How we read it: The business carrying the case: pharma's 85% half-year rise is organic, 51 net new programs, nothing bought (Gamma is plasma software, C09). It laps a weak base and the guide implies a slower second half: 3, not 4.
The results
The numbers
Sales grew 47% over the twelve months to Sep 2026, faster than the 40% in the year to Dec 2025.
Operating margin is 21%, up from −0.4% in the year to Dec 2023.
Running costs take 42¢ of each sales dollar, down from 59¢ in the year to Dec 2021.
Each dollar put into the business earns 28% a year after tax, up from 2.1% in the year to Dec 2022.
It turned 118% of sales into free cash, $130M over the last twelve months.
Yearly sales growth has ranged from +22% to +40% over the last 5 years.
The share count rose 23% in 4.8 years, and pay in shares costs 4.8% of sales.
All the numbers
Filed figures from the company's 10-K and 10-Q, read 2026-11-10. Fiscal years end in December.
| Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | 12 mo to Sep 2026 | |
|---|---|---|---|---|---|---|
| Size and growth | ||||||
| Sales | $29.5M | $38.0M | $47.3M | $58.4M | $82.0M | $110M |
| Sales growth | +22% | +29% | +24% | +24% | +40% | +47% |
| Profit | ||||||
| Gross margin | 50% | 55% | 51% | 55% | 59% | 63% |
| Operating margin | −9.3% | 0.9% | −0.4% | 1.7% | 9.0% | 21% |
| Net margin | −9.2% | 2.7% | 14% | 6.5% | 9.2% | 18% |
| What growth costs, per sales dollar | ||||||
| Selling, general and admin | 51% | 47% | 43% | 43% | 40% | 34% |
| Pay in shares | 7.7% | 6.0% | 6.0% | 4.5% | 5.2% | 4.8% |
| Capital spending | 1.1% | 0.3% | 0.6% | 0.7% | 1.5% | 0.9% |
| Cash | ||||||
| Cash from operations | $15.2M | $25.3M | $27.6M | $22.9M | $52.5M | $131M |
| Free cash flow | $14.9M | $25.2M | $27.4M | $22.5M | $51.2M | $130M |
| Balance sheet | ||||||
| Cash and short-term investments | $7.39M | - | - | - | - | - |
| Debt | - | - | - | $0 | $8.00M | $5.35M |
| Returns and shares | ||||||
| Return on capital | - | 2.1% | −0.8% | 3.4% | 13% | 28% |
| Shares (diluted) | 51.0M | 52.9M | 54.2M | 55.6M | 59.6M | 62.7M |
What growth costs
Growth has made Paysign steadily more profitable. Office, sales and admin costs rise much more slowly than sales, so each new dollar of revenue keeps more profit. It reports no research spending; it builds its software and spreads that cost over later years instead.
The evidence under this - 2 claims
Gross margin rose from 38.6% to 61.0% over the same span, so much of the widening came from the shift toward pharma rather than from fixed costs alone (C03).
The last report (9 Nov)
Quarter ended September 2026, filed figures.
Q3 2026 revenue was $30.8M, up 42.6%. Copay programs more than doubled in sales, to $16.6M, and the operating margin rose to 23.8% from 7.3% with no one-off gain. The company raised its profit forecast and kept its sales forecast.
Against that, a plasma customer said 113 of its centers will move to another provider by year-end, about $11.3M a year of revenue. Paysign expects about 445 to 450 centers at year-end, down from 562.
On the call, management said the customer is leaving for its banking partner, not over service, and expects to win replacements. The 10-Q says the loss reaches into 2027.
What it did to the thesisEvery number the thesis asked for came in, so the copay business is growing fast with real profit. The 113 centers cost plasma revenue, and the call did not change that. The shares remain dear, so the view stays Unattractive.
The quarter in detail
Sales growth from the previous quarter, filed figures.
Earnings per share $0.11 against $0.09 expected.
The evidence under this - 6 claims
- 2026-11-09editedRe-struck on the decaying fade the owner chose on 9 November: after the stated path each year closes 30% of the gap to 4%, and an analysts' margin is cut by their gap to the filed operating profit.
- 2026-11-09editedRe-struck on the decaying fade the owner chose on 9 November: after the stated path each year closes 30% of the gap to 4%, and an analysts' margin is cut by their gap to the filed operating profit.
- 2026-11-09editedthe business re-valued in three stages at an 8% required return, with analysts' margins put on the filed basis, after the day's review
- 2026-11-09editedQ3 2026 release: 562 centers, and the notice that 113 centers leave by year-end
- 2026-11-09editedQ3 2026 release: 167 programs, 62 net added in twelve months; year-end guide 190 to 195
- Guidance was raised twice in 2026 and beaten at every line in Q1, so the risk runs to under-guiding as much as over.
- The H2 guide rests on plasma rising and pharma falling seasonally, and the Q2 net income used a 14.5% tax rate the guide does not repeat.
- 2026-11-09editedQ3 2026 release raised the profit guide and held revenue; Q3 beat its own guide on revenue, margin, net income and adjusted EBITDA
- Management said the reason is the customer's banking relationship; the 10-Q gives no reason and no replacement customer is named, only 'discussions with a couple of prospective new plasma clients'.
- Plasma centers fell by 33 net in the year to September, so replacement has not yet outrun losses.
What management did with the money
Insiders in 2026Q2: 8 purchases and 21 sales, from their Form 4 filings.
The price, and where we disagree
In short. Priced for perfection. The price is about 189% of what we think the business is worth, at an 8% yearly return.
The shares more than doubled in a year, and most of the rise came from buyers paying more for each dollar of sales rather than from sales themselves. They jumped 29.3% the day after the Q2 2026 results.
The next test is the Q4 report, expected in March 2027, with Paysign's first guide for 2027 and its center count after 113 leave.
The evidence under this - 4 claims
- Guidance was raised twice in 2026 and beaten at every line in Q1, so the risk runs to under-guiding as much as over.
- The H2 guide rests on plasma rising and pharma falling seasonally, and the Q2 net income used a 14.5% tax rate the guide does not repeat.
- 2026-11-09editedQ3 2026 release raised the profit guide and held revenue; Q3 beat its own guide on revenue, margin, net income and adjusted EBITDA
- 2026-11-09editedQ3 2026 release: 167 programs, 62 net added in twelve months; year-end guide 190 to 195
How we value it
- Method
- Cash the business will produce, in three stages
- Required return
- 8%
- Long-run growth
- 4%
- Moat
- An average moat
| Bear | Base | Bull | |
|---|---|---|---|
| Sales growth, years 1 to 3 | 8.6%, 9.6% | 17.1%, 19.1% | 21.4%, 23.9% |
| Normal operating margin | 12.7% | 15.8% | 17.4% |
| Return on new capital after year ten | 8% | 12% | 15% |
| Value a share | $3.32 | $6.62 | $9.07 |
- Price
- $12.51
- Priced on
- 9 Nov
- Price as a share of the base value
- 189%
- Starting growth the price pays for
- 50.6%
- Yearly return the price offers on the base case
- 6.1%
- Risk check: valued at 10%, the rate for a cyclical or indebted business
- $4.43
Where each figure comes from
| Figure | Source | Where exactly |
|---|---|---|
| Sales, the last twelve months | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 10 Nov 2026; the four quarters to that date. |
| Operating margin today | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 10 Nov 2026; the four quarters to that date. |
| Tax rate | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 10 Nov 2026; the four quarters to that date. |
| Sales per dollar of new capital | Filed report | Annual report (10-K) for the period to 31 Dec 2025, filed 25 Mar 2026: the year's sales over its operating capital, held to between 0.5 and 6. |
| Shares | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 10 Nov 2026; the diluted share count. |
| Cash and investments | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 10 Nov 2026; the balance sheet on that date. |
| Debt | Filed report | Quarterly report (10-Q) for the period to 30 Sep 2026, filed 10 Nov 2026; the balance sheet on that date. |
| Sales growth, years 1 to 3 | Analysts' forecasts | FMP's consensus for the years to 31 Dec 2026, 31 Dec 2027 and 31 Dec 2028: the average of 1 to 3 analysts' revenue estimates, 16.4%, 18.2%. FMP publishes how many analysts, not who they are. |
| Normal operating margin | Analysts' forecasts | FMP's consensus operating margin for the year to 31 Dec 2028, the average of one analyst's estimates, 20.2%, less stock pay of 4.8% of sales: 15.5%, which the base case takes as 15.8%. FMP publishes how many analysts, not who they are. |
| Return on new capital after year ten | Our method's rule | Set by our reading of the moat: the 8% rate with none, 12% with an average one, 15% with a strong one; the bear case earns the rate. |
| The bear and bull cases | Our method's rule | Our method's spread: the bear case takes half the growth and a fifth off the margin, the bull a quarter more growth and a tenth more margin. |
| Price | Market price | FMP's closing price on 9 Nov 2026. |
What each case rests on
Bear caseGrowth runs at half the analysts' path, 9% and 10%, the margin settles a fifth lower at 12.7%, and new capital earns only the 8% rate: the downturn test.
Base caseRevenue grows 17% and 19% over the next two years, the analysts' path (C54) measured from the twelve months to September, then fades toward 4%, closing 30% of the gap each year; the margin moves to 15.8%, the analysts' year-three figure after stock pay.
Bull caseGrowth runs a quarter above the analysts' path, 21% and 24%, the margin reaches 17.4%, and new capital earns 15%.
What moves the base value
| Lower | Higher | |
|---|---|---|
| Growth in years 1 to 3, a quarter lower or higher | $5.72 | $7.64 |
| The normal margin, 15% lower or higher | $5.67 | $7.56 |
| Capital per dollar of growth, a quarter more or less | $6.53 | $6.67 |
| Return on new capital after year ten, at the rate or one step up | $5.32 | $7.13 |
| The rate, a point higher or lower | $5.31 | $8.79 |
| Long-run growth a point lower | $5.95 | - |
Value a share as growth and margin change
| Normal margin ↓ · growth → | 50% | 75% | 100% | 125% | 150% |
|---|---|---|---|---|---|
| 12.6% | $4.01 | $4.64 | $5.36 | $6.17 | $7.09 |
| 14.2% | $4.47 | $5.18 | $5.99 | $6.90 | $7.94 |
| 15.8% | $4.93 | $5.72 | $6.62 | $7.64 | $8.79 |
| 17.4% | $5.38 | $6.25 | $7.25 | $8.37 | $9.65 |
| 19% | $5.84 | $6.79 | $7.88 | $9.11 | $10.50 |
Growth is shown as a share of the base case's. Green: the price is at or under 80% of that value. Red: at or over 120%.
How we read the multiple
Buyers pay about 39 times the last four quarters' profit, against its usual 30. On the company's raised forecast for this year it is 33 times, and about 29 times what its two analysts expected for 2027 before this report.
Those analysts saw sales growth slowing to 16% next year. If they are right, the shares are still dear in 2028. The price makes sense only if growth stays near 30% for several more years.
Against its own history. Buyers now pay far more for each dollar of sales than they have in recent years, so the rise is enthusiasm as much as progress.
The evidence under this - 3 claims
- Guidance has been raised twice this year; if 2026 lands at the Q2 run-rate plus seasonality the multiple is lower than 35.2.
- Trailing earnings include a 45.4% tax rate in Q4 2025 that depresses the trailing figure.
- 2026-11-09editedre-struck on the raised guide and the Q3 diluted share count, at the 6 November close
- 2026-11-10editedRe-struck at the 9 November close of $12.51 after the 10-Q: the shares fell 15% from the close the multiples were struck at
- Guidance was raised twice in 2026 and beaten at every line in Q1, so the risk runs to under-guiding as much as over.
- The H2 guide rests on plasma rising and pharma falling seasonally, and the Q2 net income used a 14.5% tax rate the guide does not repeat.
- 2026-11-09editedQ3 2026 release raised the profit guide and held revenue; Q3 beat its own guide on revenue, margin, net income and adjusted EBITDA
Priced against its rivals
None of the listed rivals above sells the same thing to the same buyers as a large part of what it does. A price comparison needs at least two, so the price is judged against its own history instead.
Private or foreign rivals that cannot be priced: Onbe, Cencora (copay offering).
The bet: what it pays if it works
This bet is on one business only: the drug-copay programs, which grow far faster than the rest. Paying plasma donors, the older half, is counted separately at the price the market paid for the company when it was mostly plasma.
If copay programs keep being added at their recent pace for two more years, the stock is worth less than today, so this is an expensive bet. If the copay business stalls, the plasma half and the stalled copay business cover a little under half of today's price.
| Pharma industry revenue in two to three years | Programs at 2026's average revenue needed | At the stated multiple |
|---|---|---|
| $47.85M | about 131 at 100% kept | 0.5× |
| $95.50M (the big win) | about 262 at 100% kept | 0.8× |
| $127.00M | about 348 at 100% kept | 1.0× |
To pay 2× (a Fair bet) it would need about $282.18M of Pharma industry revenue (about 773 programs at 2026's average revenue); to pay 5× (a Cheap bet), about $763.87M of Pharma industry revenue (about 2.1K programs at 2026's average revenue), at the same multiple.
Each row is Pharma industry alone, plus the rest of the company (Plasma industry and other cards) counted at about $194.70M.
The steps it has to take
- Done 55 net copay programs added in 2025 and 51 in the twelve months to June 2026
- Done 2025 pharma revenue up 167.8% to $33.89M
- In progress Q3 2026: 165 to 170 programs and revenue of $28.5M to $30.0M due 2026-11
- In progress 2026 pharma revenue of about $56.5M inside the raised full-year guide due 2027-03
- Not started 2027 revenue guidance at or above $150M, about 30% growth due 2027-03
- Not started 2028 pharma revenue near $95.5M on 40 or more net programs a year due 2029-03
The detail behind the label
The evidence under this - 5 claims
- 2026-11-09editedQ3 2026 release: 167 programs, 62 net added in twelve months; year-end guide 190 to 195
The equal split was stated in March, before the raise; if the raise was mostly pharma, pharma is larger than half.
- 2026-11-09editedthe March split put pharma at $56.5M; nine months already reached $46.95M, so the estimate was re-derived from the Q3 release
The vendor's ratio series is advisory, and the six-year median includes years of losses and a smaller pharma line, so it prices plasma only roughly.
Where we disagree with the market
Paysign is a fast-growing healthcare payments company, and the plasma worries and drug-policy fears are behind it.
The copay growth is real, but 113 plasma centers are leaving, the software purchase failed, and the price already pays for years of fast growth.
The market reads the headline figures. The center losses and the cancelled payment on the failed purchase sit in the notes and in the release's last paragraphs, not in its opening lines.
The case against us: the company keeps beating its own quarterly forecast and raising its profit forecast, and if copay programs keep compounding, today's price will look cheap.
What analysts say, and the evidence
The evidence under this - 5 claims
- 2026-11-09editedQ3 2026 release: 562 centers, and the notice that 113 centers leave by year-end
- 2026-11-09editedQ3 2026 release: 167 programs, 62 net added in twelve months; year-end guide 190 to 195
What could go wrong, and how we would know
The risks
- A rule against copay-draining plans. Paysign's selling point is blocking insurers' maximizer plans. A federal ban would shrink the problem it is paid to solve.
- One drug maker looms large. A single client is 36% of the money Paysign is owed, up from 31% at the end of 2025.
- Plasma centers walking away. A customer is moving 113 centers, about $11.3M of yearly sales, to another provider by year-end; 33 net centers went in the last year.
- A far larger rival. McKesson's copay service saves patients about $10B a year to Paysign's $1B, and programs Paysign wins from others can be won back.
- Insiders are selling. Twenty open-market sales and no purchases in a year; share count up 7.1%.
The evidence under this - 8 claims
- State bans did not remove accumulators and did not touch maximizers, and most employer plans fall under federal ERISA law that states cannot reach (IQVIA, management).
- A ban would also stop insurers draining programs mid-year, which could raise claim volume Paysign is paid on.
Congress has repeatedly seen bills to count copay aid toward deductibles; management is the party most exposed if one passes, so its forecast is interested.
- 2026-11-10editedThe September 10-Q gives the receivables split by client
- 2026-11-09editedQ3 2026 release: 562 centers, and the notice that 113 centers leave by year-end
Management says closures cost little because donors move to nearby Paysign centers, and revenue per center rose 8.5% while centers fell.
What we still do not know
- How many copay programs Paysign loses to rivals. It reports only the net count.
- What it charges per program and per claim, against McKesson and private rivals. Nobody publishes it.
- Which collector sold centers to a rival card provider, and which provider won them.
- When, if ever, the FDA clears its plasma software.
The evidence under this - 4 claims
- 2026-11-09editedQ3 2026 release: 167 programs, 62 net added in twelve months; year-end guide 190 to 195
- 2026-11-09editedQ3 2026 release: 562 centers, and the notice that 113 centers leave by year-end
- The timetable has already slipped at least twice, from Q4 2025 to 'first quarter, second quarter' of 2026, and the Q1 2026 call would say nothing beyond 'discussions back and forth'.
- The FDA's 510(k) database shows no clearance for Paysign, Gamma or Apherion as of 2026-09-27.
What would change our view
- Unattractive→NeutralThe price falls back within 20% of fair value
It needs:
- ○The share price falls to about $7.94, back within 20% of what we think the business is worth.about $7.95 today, 45% below the last close
- Unattractive→AttractiveThe price falls 20% under fair value
It needs:
- ○The share price falls to about $5.30, 80% of what we think the business is worth.about $5.30 today, 63% below the last close
- Unattractive→AttractiveGrowth holds well above the panel into 2027
It needs all of:
- ○Paysign guides 2027 revenue of $150M or more, about 30% growth.checked at the next results, due by 10 Mar
- ○Its plasma center count is at or above 445 at the end of 2026, once 113 centers leave, with no further customer moving.checked at the next results, due by 10 Mar
We would also be wrong if
- A federal rule bars insurers' maximizer plans in employer health plans.
- One drug maker's bills pass half of what Paysign is owed, or a top-ten maker leaves.
What is coming
- March 2027 Q4 and full-year 2026 results with 2027 guidance: Whether 2027 revenue guidance reaches about $150M, centers hold at the guided 445 to 450 once the 113 move, programs reach 190 to 195, and operating margin stays above 21%.
Every dated event ahead
- March 2027 Q4 and full-year 2026 results with 2027 guidance: Whether 2027 revenue guidance reaches about $150M, centers hold at the guided 445 to 450 once the 113 move, programs reach 190 to 195, and operating margin stays above 21%.
- 30 June 2027 2027 annual meeting vote on more equity-plan shares: How many new shares the board asks for, including the units promised to Gamma's owner, and so how fast the diluted count keeps rising.
Since we wrote this
- 11 NovThesis reviewUnattractive, high conviction: the view holds even in our best caseConviction re-graded on the new anchors: how robust the view is, not whether anything is still open.
- 10 NovEarningsCall read; price fell 15%, still about 181% of valueThe call said the customer left for its bank, not over service; the loss runs into 2027. At 181% of a value near $6.92 the view stays Unattractive.
- 9 NovEarningsQ3 beat on every line, but 113 plasma centers leaveRevenue rose 43% and margin tripled the year before; a plasma customer is moving 113 centers by year-end. The price is higher, so Neutral holds.
- 9 NovThesis reviewUnattractive: priced at 231% of a value near $6.35Re-valued in three stages at an 8% return, the method now drawn on every thesis: the price sits beyond the 20% margin of safety.
- 5 OctThesis reviewThe bet now names what it ridesThe owner asked that every bet name the macro trend behind it, after BWXT's bet was missing its chief executive's case for nuclear over gas.
- 4 OctThesis reviewOwner's checklist: revenue streams, cost of growth, management, catalystsThe owner's checklist found the method silent on who runs the company, what growth costs, where the money comes from and what is dated ahead; this pass fills those four blocks from the proxy and filings.
- 27 SepThesis writtenNeutral, medium convictionWritten six weeks before Q3 2026 results, after the shares more than doubled on two guidance raises.
Also checked 5 times with nothing new to act on.
Sources 25
Sources - 25
Every claim above cites one of these, or states the reasoning that derived it. The quote is frozen at the date it was read: a link can rot, and an agent fetch returns a reading of a page rather than the page. Backs counts the whole claim ledger, so it can name a claim this page does not surface.
- S01primarycompany filing2026-03-25Item 1 business, the plasma center share, the competition section (classes, no names), risk factors on issuing banks, the cash flow statement, receivable concentration, the buyback authorisationbacksC01C11C25C27C28C31C45C49C50
- S02primarycompany filing2026-08-06the MD&A, the Gamma acquisition note and earn-out write-off, receivable concentration, the cash flow statement, share counts and dilution, interest incomebacksC01C02C05C07C09C25C26C27C30C31C33C40C49C50C51
- S03primarycompany release2026-08-05revenue by industry, program and center counts, revenue per center, the one-off earn-out gain, the balance sheet, the raised 2026 guidance and the Q3 2026 guidebacksC02C03C04C05C06C07C26C31C35C39
- S04primarycompany release2026-03-242025 revenue by industry, centers and programs at year end, the first 2026 guidance, the plasma inventory explanation, the Gamma closing and BECS statusbacksC03C06C07C11C29C31C40
- S05primarycompany release2025-08-05the quarter plasma revenue fell 4.7% on industry plasma oversupply, 123 centers added on 2025-06-16, 97 programsbacksC37
- S06primarytranscript2026-05-12Paysign Q1 2026 earnings call transcript (FMP), held 2026-05-12management's remarks on programs, claims, the $540M of Q1 assistance and plasma closures; three analysts' questions, including whether Apherion earns revenue (it does not) and the $6M left to pay Gamma's sellers
Currently, we're having discussions back and forth with the FDA, and that's really all I can say right now.
backsC10C20C27C44 - S07primarytranscript2026-03-24Paysign Q4 2025 earnings call transcript (FMP), held 2026-03-24the $1B of 2025 assistance and $325M of claimed savings, the transitions-versus-launches mix, the named rivals McKesson and Cencora, and the argument that federal action on maximizers is not expected
In 2025, our platform helped deliver nearly $1 billion in financial assistance to patients, supporting access to high-cost therapies for more than 840,000 individuals. At the same time, we help manufacturers better control how those dollars are spent, which is one of the key value propositions we provide. A key differentiator of our platform is our dynamic business rules technology, which helps pharmaceutical manufacturers avoid unnecessary costs associated with co-pay maximizer programs. In 2025 alone, this solution saved our clients over $325 million.
backsC19C20C21C24C38 - S08primarytranscript2025-11-12Paysign Q3 2025 earnings call transcript (FMP), held 2025-11-12the BECS clearance timetable as management stated it in November 2025
we were to get through the FDA approval sometime in fourth quarter. Going into first quarter.
backsC10 - S09primarycompany filing2026-09-2720 open-market sales and no purchases; the Rule 10b5-1 flag on each salebacksC32
- S10secondaryvendor data2026-09-27Research pack, PAYS, 2026-09-27 (FMP market data, FINRA short interest)price, the 252-session decomposition, daily closes around each print, the two-analyst estimate panel, the ratings series and short interestbacksC33C35C36C37C38C39C45
- S11primaryindustry data2024-05-07IQVIA Institute press release, 'U.S. Medicines Spending Grew in 2023 as Greater Access Offset COVID-19-related Decline' IQVIA Institutethe size of manufacturers' copay assistance, measured outside the industry's sellers
This amount is after $23Bn in copay assistance programs provided by manufacturers, with patients using copay cards for nearly one-third of brand commercial prescriptions in the top 10 therapy areas and 63% of obesity prescriptions.
backsC16 - S12primaryindustry data2024-03what maximizers and accumulators take from manufacturers' support budgets, and that state bans slowed but did not stop them
Nevertheless, in 2023, maximizers accounted for an estimated $2.7B (23%) of total patient support spend in the U.S.
backsC17 - S13secondaryindustry data2026-02Drug Channels, 'Copay Accumulators and Maximizers in 2025: Popular, Profitable, and Problematic' (MMIT data) Drug Channels Institutehow many commercial lives sit in plans that divert copay aid, measured by a benefits-data firm
For 2025, we estimate that only 39% of covered lives are enrolled in plans with accumulators and a comparable number are in plans with maximizers.
backsC18 - S14secondaryother2026-01Peter Jaworski (Georgetown University), 'America's Plasma Contribution to the World: 2025' Peter Jaworski, Georgetown Universityan outside count of US plasma centers and collections, and the device-driven yield gain
As of December 31, there are 1,247 plasma collection centers in the United States (including four centers in Puerto Rico). Centers may not have grown by 8%, but plasma collections grew by 8.41% from 57.6 to 62.5 million liters.
backsC11C12C14 - S15primaryother2026-09-27CSL Plasma, donor FAQ CSL Plasmathat CSL Plasma pays its donors on Paysign cards, said by the customer
Donors with questions can call Paysign Customer Service at 888-522-4853 for assistance.
backsC12 - S16primaryother2026-09-27a private rival selling the same donor payout product
Pay donors and trial participants instantly with payment choices that offer convenient, secure access to funds.
backsC13 - S17primarycompany filing2026-05-20the incumbent donor management system NexLynk DMS, wired to its own collection device, and the device yield gainsbacksC12C14C15
- S18primarycompany filing2026-05-08the scale of McKesson's affordability business and a Justice Department demand about its copay coupon administrationbacksC21C22
- S19primaryregulator2026-09-27no 510(k) clearance on record for Paysign's donor management system
error code NOT_FOUND, message: No matches found!
backsC10 - S20primarycompany filing2026-03-26directors and executive officers with tenure, the summary compensation table and its footnotes on bonus and stock awards, pay versus performance, and beneficial ownership at March 19, 2026backsC46C47C48
- S21primarycompany release2026-11-09revenue by industry, program and center counts, the 113-center transfer notice, margins, the income statement, the balance sheet and the raised 2026 guidancebacksC04C05C29C41C52C53
- S22primarycompany filing2026-11-09trailing revenue, operating profit, stock pay, tax, debt, cash and the diluted share countbacksC55
- S23secondaryvendor data2026-11-09the analysts' average revenue and operating profit for the next three fiscal years, and the closebacksC54C55
- S24primarytranscript2026-11-09management's account of the departing plasma customer, the year-end program and center outlook, the Q4 effect of the transfer and the status of the Apherion reviewbacksC56
- S25primarycompany filing2026-11-10receivables by client, the 113-center subsequent event with its quarterly revenue and gross profit, and the outlook that the loss continues into 2027backsC56